Shear Wave Elastography: A Potential Biomarker of Spinal-Bulbar & Muscular Atrophy (SBMA)
Monday, April 8, 2024
3:04pm – 3:11pm
Location: 410
Authors: Yonathan Assefa, National Institutes of Health Euan Forrest, National Institutes of Health Abdullah AlQahtani, NIH Joseph Shrader, DHHS, NIH, Clinical Center, RMD, PT Henry Roberts, National Institutes of Health / Clinical Trials Unit Katharine Alter, Clinical Center, NIH Galen Joe, National Institutes of Health Mina Jain, National Institutes of Health / Clinical Trials Unit Christopher Christopher Grunseich, NINDS, National Institutes of Health ,
In this pilot study, we set out to explore how ultrasound technology could possibly serve as a way to help develop therapies for Spinal and Bulbar Muscular Atrophy (SBMA), a dehabilitating neuromuscular disorder. We did this by exploring the untapped potential of Shear Wave Elastography (SWE) as a novel biomarker. Our findings offer a fresh perspective into the challenge of developing a reliable, sensitive marker for SBMA.
This presentation will captivate attendees with unique insights, showcasing challenges and possibilities of SWE as a diagnostic tool. We will explore the confounding factors that affected our results, emphasizing the need for larger sample sizes and further exploration. As a critical stepping stone in the search for SBMA biomarkers, our work opens up exciting avenues for the expanding role of Shear Wave Elastography in the clinical assessment of musculoskeletal disorders.